Merck & Co., Inc. (NYSE:MRK) Stock Jumps 3.6% – Still a Buy?

Merck & Co., Inc. (NYSE:MRK)’s stock price traded up 3.6% on Wednesday. The stock traded as high as $146.67 and last traded at $147.1410. Approximately 2,234,501 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 10,586,647 shares. The stock had previously closed at $141.98.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Keytruda and pipeline catalysts support earnings outlook: Keytruda sales growth, expanded indications and launches of earlier-stage products could help Merck deliver stronger third-quarter revenue ahead of its earnings report in the next few weeks. Will Keytruda Continue to Aid Merck’s Top Line in Q3 Earnings?
• Positive Sentiment: Upcoming ESMO data boosts pipeline optimism: Merck will present first-time Phase 3 results from three pivotal oncology trials, along with more than 90 additional abstracts across over 20 tumor types. Positive results could strengthen confidence in growth beyond Keytruda and help address its eventual loss of exclusivity. Merck Showcases First-Time Pivotal Phase 3 Results
• Positive Sentiment: Analyst support: Leerink Partners initiated or reiterated a Buy rating, adding to the positive sentiment around Merck’s valuation and pharmaceutical pipeline. Merck Gets a Buy from Leerink Partners
• Neutral Sentiment: Board appointment: Paul J. Diaz was elected to Merck’s board, adding healthcare and management experience but offering little immediate earnings impact. Paul J. Diaz Elected to Merck Board
• Negative Sentiment: Pipeline and competitive risks weigh on the story: Jefferies cut its peak-sales forecast for experimental eye drug remigromig by 60% after efficacy and safety concerns. Keytruda also faces biosimilar competition in 2028–2029, while Erste Group modestly reduced its 2026 and 2027 EPS estimates. Merck’s elevated valuation and reported negative operating margin could amplify downside if results disappoint. Jefferies Cuts Merck’s Remigromig Sales Forecast

Wall Street Analyst Weigh In

Several research firms have issued reports on MRK. Rothschild & Co Redburn upped their price target on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, July 6th. HSBC lifted their price objective on shares of Merck & Co., Inc. from $150.00 to $172.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Sanford C. Bernstein boosted their price objective on shares of Merck & Co., Inc. from $100.00 to $105.00 and gave the stock a “market perform” rating in a research note on Tuesday, August 4th. Berenberg Bank upped their target price on shares of Merck & Co., Inc. from $127.00 to $137.00 and gave the company a “hold” rating in a report on Friday, September 11th. Finally, Barclays upped their target price on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Seventeen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $151.92.

Merck & Co., Inc. Trading Up 3.6%

The business has a 50 day moving average of $144.52 and a two-hundred day moving average of $128.73. The firm has a market cap of $362.91 billion, a P/E ratio of 118.45, a PEG ratio of 6.72 and a beta of 0.21. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same period in the previous year, the business posted $2.13 earnings per share. The company’s revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts predict that Merck & Co., Inc. will post 2.66 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were issued a dividend of $0.85 per share. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the transaction, the executive vice president directly owned 45,509 shares of the company’s stock, valued at $6,073,631.14. This represents a 63.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Chirfi Guindo sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the sale, the executive vice president owned 46,613 shares of the company’s stock, valued at $6,106,303. This trade represents a 24.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock worth $29,977,783 in the last 90 days. Corporate insiders own 0.17% of the company’s stock.

Hedge Funds Weigh In On Merck & Co., Inc.

A number of large investors have recently made changes to their positions in MRK. BlackRock Inc. raised its holdings in shares of Merck & Co., Inc. by 0.5% in the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock valued at $29,169,479,000 after acquiring an additional 1,073,507 shares in the last quarter. State Street Corp increased its position in Merck & Co., Inc. by 0.9% during the 2nd quarter. State Street Corp now owns 120,413,256 shares of the company’s stock valued at $15,573,754,000 after buying an additional 1,087,583 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Merck & Co., Inc. by 2.3% during the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after acquiring an additional 1,934,312 shares in the last quarter. Bank of America Corp DE raised its position in shares of Merck & Co., Inc. by 10.5% in the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after purchasing an additional 2,919,780 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in Merck & Co., Inc. by 3.5% in the 4th quarter. Invesco Ltd. now owns 20,546,185 shares of the company’s stock worth $2,162,691,000 after purchasing an additional 701,249 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.